Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Mohamad Ali Hijazi, André Gessner, Nahed El‐Najjar
Cancers (2023) Vol. 15, Iss. 12, pp. 3199-3199
Open Access | Times Cited: 16

Showing 16 citing articles:

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing
Rama Rao Malla, V Sathiyapriya, Sree Makena, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1463-1463
Open Access | Times Cited: 7
Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer
Ana Luísa De Sousa‐Coelho, Gil Fraqueza, Manuel Aureliano
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 12-12
Open Access | Times Cited: 17
Therapeutic Potential and Challenges of Pioglitazone in Cancer Treatment
Maria Vasileiou, Sotirios Charalampos Diamantoudis, Christina Tsianava, et al.
Applied Sciences (2025) Vol. 15, Iss. 4, pp. 1925-1925
Open Access
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel Búrbano, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. 298-304
Closed Access | Times Cited: 3
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses
Mina Nikanjam, Kaitlyn Wells, Shumei Kato, et al.
Med (2024) Vol. 5, Iss. 7, pp. 689-717
Closed Access | Times Cited: 2
Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways
Natália F. Haddad, Sara Magura Gamaethige, Nadine Wehida, et al.
Biology (2024) Vol. 13, Iss. 6, pp. 386-386
Open Access | Times Cited: 2
Aldo-keto reductases: Role in cancer development and theranostics
Siddavaram Nagini, Prathap Reddy Kallamadi, Kranthi Kiran Kishore Tanagala, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1287-1308
Open Access | Times Cited: 2
Epithelial‑derived head and neck squamous tumourigenesis (Review)
Charles Shirima, Coralia Bleoţu, Demetrios�� Spandidos, et al.
Oncology Reports (2024) Vol. 52, Iss. 4
Closed Access | Times Cited: 2
Drug Repurposing for Cancer Treatment: A Comprehensive Review
Abdulaziz H. Al Khzem, Mohamed S. Gomaa, Mansour S. Alturki, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12441-12441
Open Access | Times Cited: 1
Immunohistochemical evidences of anticancer actions of metformin with other repurposed drug combinations and correlation with hamster fibrosarcoma tumor size
Jovan Popović, Dušica J. Popović, K Popović, et al.
Journal of the Serbian Chemical Society (2024) Vol. 89, Iss. 5, pp. 643-656
Open Access
Repurposing Drugs for Overcoming Therapy Resistance in Colon Cancer – A Review
Mahdi Darvishi, Amir Chekeni, Mohammad Fazelhosseini, et al.
Journal of Angiotherapy (2024) Vol. 8, Iss. 2
Open Access
Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review
Iqra Khan, Aisha Kamal, Salman Akhtar
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 3, pp. 1907-1929
Closed Access
Citation: Trybus, E.; Trybus, W. H1 Antihistamines—Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment. Cancers 2024, 16, 4253. https://doi.org/10.3390/cancers16244253
Ewa Trybus, Wojciech Trybus
Cancers (2024) Vol. 16, Iss. 24, pp. 4253-4253
Open Access
Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors
Alexey I. Kalinkin, В.О. Сигин, Ekaterina Kuznetsova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17343-17343
Open Access | Times Cited: 1
Effectiveness of the alternative drugs and other factors in adjuvant treatment for the malignant tumors
В. А. Чубенко
Practical oncology (2023) Vol. 23, Iss. 4, pp. 383-394
Open Access
Page 1

Scroll to top